Nulojix Reduces Risk of Kidney Transplant Rejection, Mortality in Follow-Up Study

Bristol-Myers Squibb Company announced results from the Phase 3 BENEFIT trial in kidney transplant patients receiving Nulojix (belatacept) vs. cyclosporine.

The BENEFIT trial is a seven-year, follow-up, open-label, randomized, comparative, multicenter study that enrolled 666 renal transplant recipients of standard criteria deceased donor (SCD) and living donor kidneys. Patients were randomized to one of three cohorts: FDA-approved Nulojix regimen, a less intensive dose of Nulojix (n=226), or cyclosporine (n=221). The primary endpoints were composite patient and graft survival by 12 months, rate of acute rejection by 12 months, and composite measured GFR <60 at month 12 or a decrease in measured GFR from month 3 to month 12.

RELATED: Generic Drug Found Bioequivalent to Brand for Transplant Patients

At three years, BENEFIT results demonstrated improvement in renal function in kidney transplant recipients treated with Nulojix compared to cyclosporine. Nulojix demonstrated a statistically significant 43% relative risk reduction of death or graft loss (transplant failure) in patients receiving the FDA-approved Nulojix regimen over those receiving a cyclosporine regimen (HR=0.57, P=0.0286). Data also showed that there was a statistically significant survival benefit of 52% relative risk reduction of treatment failure at five years post-transplant (HR=0.477, P=0.0045).

Nulojix is already indicated for organ rejection prophylaxis in adult EBV seropositive patients receiving a kidney transplant, in combination with basiliximab induction, mycophenolate mofetil, and corticosteroids.

For more information call (800) 321-1335 or visit